Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|SF1126||BRD4 Inhibitor 7 PI3K Inhibitor (Pan) 37||SF1126 is a prodrug of LY294002, a pan PI3K inhibitor with additional activity against BRD4, which potentially results in reduced tumor immunosuppression and inhibits tumor growth (PMID: 23355037, PMID: 27496136, PMID: 31018997).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||SF1126||Phase I||Actionable||In a Phase I trial, SF1126 demonstrated safety and preliminary efficacy in patients with a variety of advanced solid tumors (PMID: 22921184).||22921184|
|Unknown unknown||hepatocellular carcinoma||not applicable||SF1126||Preclinical - Cell line xenograft||Actionable||In a preclinical study, SF1126 inhibited proliferation of hepatocellular carcinoma cell lines in culture, and inhibited tumor growth in hepatocellular carcinoma cell line xenograft models (PMID: 27496136).||27496136|
|Unknown unknown||lung carcinoma||not applicable||SF1126||Preclinical||Actionable||In a preclinical study, SF1126 decreased tumor immunosuppression and reduced tumor growth in syngeneic mouse lung carcinoma models (PMID: 31018997).||31018997|
|HRAS G12V||malignant glioma||sensitive||SF1126||Preclinical - Cell line xenograft||Actionable||In a preclinical study, SF1126 inhibited Akt activation, proliferation, and migration of transgenic mouse glioma cells expressing HRAS G12V in culture, and suppressed tumor growth in xenograft models (PMID: 25425962).||25425962|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03059147||Phase I||SF1126||A Study of Single Agent SF1126 Inhibitor in Patients With Advanced Hepatocellular Carcinoma||Active, not recruiting|
|NCT02644122||Phase II||SF1126||SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes||Terminated|
|NCT02337309||Phase I||SF1126||SF1126 for Patients With Relapsed or Refractory Neuroblastoma||Terminated|